IN2012DN02304A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN02304A IN2012DN02304A IN2304DEN2012A IN2012DN02304A IN 2012DN02304 A IN2012DN02304 A IN 2012DN02304A IN 2304DEN2012 A IN2304DEN2012 A IN 2304DEN2012A IN 2012DN02304 A IN2012DN02304 A IN 2012DN02304A
- Authority
- IN
- India
- Prior art keywords
- aging
- arnox
- disorders
- recombinant
- nadh oxidase
- Prior art date
Links
- 102000001708 Protein Isoforms Human genes 0.000 abstract 3
- 108010029485 Protein Isoforms Proteins 0.000 abstract 3
- 108010007843 NADH oxidase Proteins 0.000 abstract 2
- 230000032683 aging Effects 0.000 abstract 2
- 230000002431 foraging effect Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000003298 DNA probe Substances 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 230000003712 anti-aging effect Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 210000001124 body fluid Anatomy 0.000 abstract 1
- 239000010839 body fluid Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000002537 cosmetic Substances 0.000 abstract 1
- 230000018109 developmental process Effects 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 210000003296 saliva Anatomy 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 210000002700 urine Anatomy 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/90209—Oxidoreductases (1.) acting on NADH or NADPH (1.6), e.g. those with a heme protein as acceptor (1.6.2) (general), Cytochrome-b5 reductase (1.6.2.2) or NADPH-cytochrome P450 reductase (1.6.2.4)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Analytical Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Described are cell surface and circulating markers for aging related disorders (specific isoforms of NADH oxidase (arNOX)). Recombinant age-related NADH oxidase isoforms and their coding sequences and methods for detecting arNOX isoform presence and quantitation in tissues and in blood, sera, urine, saliva, perspiration and in other body fluids, are provided. Recombinant arNOX proteins are useful in preparing antigens for use in the generation of monoclonal and polyclonal antibodies as well as immunogenic compositions for diagnosis and treatment of aging disorders. DNA probes based on the DNA sequence information provide may be used to identify individuals at risk for aging disorders and for development of preventative or therapeutic interventions or anti-aging cosmetic or other formulations of benefit in slowing the aging process in mammals.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23436809P | 2009-08-17 | 2009-08-17 | |
| PCT/US2010/045745 WO2011022387A1 (en) | 2009-08-17 | 2010-08-17 | Cloning and expression of arnox protein transmembrane 9 superfamily (tm9sf), methods and utility |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN02304A true IN2012DN02304A (en) | 2015-08-21 |
Family
ID=43607300
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2304DEN2012 IN2012DN02304A (en) | 2009-08-17 | 2010-08-17 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20120315629A1 (en) |
| EP (1) | EP2467392A4 (en) |
| JP (1) | JP2013502217A (en) |
| CN (1) | CN102574889A (en) |
| CA (1) | CA2771277A1 (en) |
| IN (1) | IN2012DN02304A (en) |
| WO (1) | WO2011022387A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011109525A1 (en) | 2010-03-02 | 2011-09-09 | Nox Technologies, Inc. | Aging-Related Circulating Particle-Associated Lipoprotein B Oxidase (apoBNOX) and Inhibitors Thereof |
| EP3013961A1 (en) * | 2013-06-25 | 2016-05-04 | Mor-Nuco Enterprises, Inc. | Growth-related enox proteins from plants with yield enhancement potential, sequences and methods |
| CN114774418B (en) * | 2022-04-19 | 2023-11-14 | 深圳市人民医院 | shRNA molecules and their application in knocking down TM9SF2 gene expression |
| CN115772574A (en) * | 2022-10-27 | 2023-03-10 | 华南农业大学 | Chicken TM9SF2 gene identification method and prokaryotic expression of extramembranous domain thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030175787A1 (en) * | 1997-10-28 | 2003-09-18 | Incyte Corporation | Vesicle membrane proteins |
| US20070203083A1 (en) * | 2003-06-13 | 2007-08-30 | Mootha Vamsi K | Methods Of Regulating Metabolism And Mitochondrial Function |
| US7473531B1 (en) * | 2003-08-08 | 2009-01-06 | Colora Corporation | Pancreatic cancer targets and uses thereof |
| WO2005019258A2 (en) * | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US8014957B2 (en) * | 2005-12-15 | 2011-09-06 | Fred Hutchinson Cancer Research Center | Genes associated with progression and response in chronic myeloid leukemia and uses thereof |
| WO2008121324A2 (en) * | 2007-03-30 | 2008-10-09 | Abbott Laboratories | Recombinant expression vector elements (reves) for enhancing expression of recombinant proteins in host cells |
| CA2713193C (en) * | 2008-01-25 | 2018-01-02 | Exosomics S.p.A. | A metastatic human tumor associated molecule, methods to detect both activated gene and protein and to interfere with gene expression |
-
2010
- 2010-08-17 WO PCT/US2010/045745 patent/WO2011022387A1/en not_active Ceased
- 2010-08-17 CN CN2010800366427A patent/CN102574889A/en active Pending
- 2010-08-17 US US13/390,795 patent/US20120315629A1/en not_active Abandoned
- 2010-08-17 JP JP2012525639A patent/JP2013502217A/en not_active Withdrawn
- 2010-08-17 EP EP10810479.5A patent/EP2467392A4/en not_active Withdrawn
- 2010-08-17 IN IN2304DEN2012 patent/IN2012DN02304A/en unknown
- 2010-08-17 CA CA2771277A patent/CA2771277A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013502217A (en) | 2013-01-24 |
| WO2011022387A8 (en) | 2012-03-29 |
| CN102574889A (en) | 2012-07-11 |
| CA2771277A1 (en) | 2011-02-24 |
| EP2467392A4 (en) | 2013-06-19 |
| US20120315629A1 (en) | 2012-12-13 |
| EP2467392A1 (en) | 2012-06-27 |
| WO2011022387A1 (en) | 2011-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20092522L (en) | Compositions and Methods for Treating Cancer with Cupredoxins and CPG Rich DNA | |
| EA201170635A1 (en) | COMPOSITIONS, METHODS OF OBTAINING AND APPLICATION OF THE FRAMEWORK ON THE BASIS OF FIBRONECTIN TYPE III DOMAIN | |
| AU2008298744A8 (en) | MiRNA expression in human peripheral blood microvesicles and uses thereof | |
| BRPI0811210A2 (en) | IMAGE TRAINING AGENT, PHARMACEUTICAL COMPOSITION, METHODS FOR PREPARATION OF A IMAGE TRAINING AGENT, FORMATIC OPTICAL IMAGE FORMATION OF A MAMMALIAN BODY AND DETECTION, STAGE ASSESSMENT, PROGRESS MONITOR MONITORING DIAGNOSIS OR MONITORING DIAGNOSIS COLORRETAL CANCER TREATMENT OF A MAMMALIAN'S BODY, AND, KIT FOR PREPARING PHARMACEUTICAL COMPOSITION. | |
| WO2008108803A3 (en) | Immune cell biosensors and methods of using same | |
| WO2008103645A8 (en) | Prostate cancer and melanoma antigens | |
| EP2068929A4 (en) | Method for detecting and treating skin disorders | |
| WO2010041046A3 (en) | Granin proteins as markers of heart disease | |
| FI2398902T3 (en) | Methods and compositions for diagnosis and treatment of cancer | |
| WO2011156734A3 (en) | Method of characterizing vascular diseases | |
| MX347871B (en) | Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate. | |
| WO2005040421A3 (en) | Prognostic and diagnostic markers for cell proliferative disorders of the breast tissues | |
| ES3005161T3 (en) | Diagnostic method of a skin showing signs of aging | |
| WO2011022387A8 (en) | Cloning and expression of arnox protein transmembrane 9 superfamily (tm9sf), methods and utility | |
| IL190401A0 (en) | Antibodies against april as biomarkers for early prognosis of lymphoma patients | |
| RU2012103932A (en) | BIOMARKER FOR PATIENT SELECTION AND RELATED WAYS | |
| US20180196064A1 (en) | Method of evaluating cellulite and method of evaluating cellulite-effective drug using fibulin-3 and/or sarcoglycan gamma as an indicator | |
| BRPI0818957B8 (en) | isolated gene, expression vector, genetically modified host cell and method for preparing an immunogenic macromolecule | |
| EA200970332A1 (en) | NEW ANTIGENS AND ANTIBODIES ASSOCIATED WITH THE PANCREATIC ADHENOCARCINOMA | |
| Shamsadini et al. | Leopard syndrome | |
| WO2012144755A3 (en) | Composition and kit for the diagnosis of mild cognitive impairment, which measure an expression level of lipocalin-2, and method for providing information for the diagnosis of mild cognitive impairment | |
| WO2009021235A3 (en) | Methods and compositions for treating cancer | |
| WO2009069007A3 (en) | Composition and method for prediction of complicated disease course in crohn's disease | |
| WO2009148363A3 (en) | Method for diagnosing parasitic disease | |
| MX2013002820A (en) | ESTRAFICATION OF PATIENTS WITH CANCER TO DETERMINE SUSCEPTIBILITY TO TREATMENT WITH PTK2 INHIBITORS. |